Crescent Biopharma, Inc.(CBIO)

$17.08—

Chart

Crescent Biopharma, Inc.(CBIO)

NASDAQ

$17.08—

Chart Studio

CBIO(CBIO)

CBIO

Overview Notebook Intelligence Chart History Fundmntls TTM Earnings Analysts News Financials Segments Insiders Institl.DCF Peers

Q3 2026 EPS Estimate

$-0.78

Jul 30, 2026 · Reports after close

Revenue Estimate

$357,143

Analyst Sentiment

Wall St. Consensus

Buy

13 analysts·Moderate coverage

Score

8 Buy (62%)5 Hold (38%)0 Sell (0%)

Rating Breakdown

Strong Buy

00%

Buy

862%

Hold

538%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear

$29.00

+69.8%

Consensus

$35.00

+104.9%

Bull

$35.00

+104.9%

12-Month Target Range13 analysts

$29.00$35.00$35.00

Current $17.08Consensus

Current Price

$17.08

Upside to Consensus

$17.92

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)

FY2027

Rev+206.40%

EPS—

FY2028

Rev+46.87%

EPS—

FY2029

Rev+104.07%

EPS—

Raw consensus estimates (low / average / high) from covering analysts.

Annual

Metric	FY2026E	FY2027E	FY2028E	FY2029E	FY2030E
Revenue Avg	$2M	$6M	$8M	$17M	$77M
Low	$2M	$5M	$8M	$16M	$74M
High	$2M	$7M	$10M	$21M	$96M
EBITDA Avg	$-1M	$-3M	$-5M	$-10M	$-46M
Low	$-1M	$-4M	$-6M	$-13M	$-58M
High	$-1M	$-3M	$-5M	$-10M	$-44M
EBIT Avg	$-1M	$-3M	$-5M	$-10M	$-46M
Low	$-1M	$-4M	$-6M	$-13M	$-58M
High	$-1M	$-3M	$-5M	$-10M	$-44M
Net Income Avg	$-33M	$-34M	$-36M	$-39M	$-36M
Low	$-34M	$-38M	$-45M	$-52M	$-47M
High	$-32M	$-29M	$-27M	$-37M	$-34M
EPS Avg	$-3.20	$-3.25	$-3.46	$-3.74	$-3.42
Low	$-3.27	$-3.65	$-4.33	$-4.96	$-4.54
High	$-3.06	$-2.80	$-2.59	$-3.53	$-3.23
Analysts (Rev / EPS)	6 / 4	4 / 3	6 / 5	5 / 1	3 / 1

Quarterly

Metric	Q3 2026	Q4 2026	Q1 2027	Q2 2027	Q3 2027	Q4 2027
Revenue Avg	$357,143	$357,143	$311,180	$230,203	$170,298	$125,982
Low	$357,141	$357,143	$311,180	$230,203	$170,298	$125,982
High	$357,144	$357,143	$311,180	$230,203	$170,298	$125,982
EBITDA Avg	$-214,285	$-214,285	$-186,708	$-138,121	$-102,178	$-75,589
Low	$-214,286	$-214,285	$-186,708	$-138,121	$-102,178	$-75,589
High	$-214,284	$-214,285	$-186,708	$-138,121	$-102,178	$-75,589
EBIT Avg	$-214,285	$-214,285	$-186,708	$-138,121	$-102,178	$-75,589
Low	$-214,286	$-214,285	$-186,708	$-138,121	$-102,178	$-75,589
High	$-214,284	$-214,285	$-186,708	$-138,121	$-102,178	$-75,589
Net Income Avg	$-25M	$-27M	$-24M	$-26M	$-30M	$-31M
Low	$-26M	$-27M	$-24M	$-26M	$-30M	$-31M
High	$-23M	$-27M	$-24M	$-26M	$-30M	$-31M
EPS Avg	$-0.82	$-0.88	$-0.80	$-0.86	$-1.00	$-1.01
Low	$-0.86	$-0.88	$-0.80	$-0.86	$-1.00	$-1.01
High	$-0.76	$-0.88	$-0.80	$-0.86	$-1.00	$-1.01
Analysts (Rev / EPS)	7 / 3	4 / 1	4 / 1	3 / 1	3 / 1	3 / 1

Earnings Surprises

Recent Analyst Actions

Feb 26, 2026Stifel Nicolaus

Crescent Biopharma Inc (CBIO) PT Lowered to $29 at Stifel

Target:$29.00

+134.9%from $12.35

Jan 28, 2026Piper Sandler

Crescent Biopharma initiated with an Overweight at Piper Sandler

Target:$35.00

+210.6%from $11.27

Jan 21, 2026Guggenheim

Crescent Biopharma initiated with a Buy at Guggenheim

Target:$35.00

+150.4%from $13.98

Dec 4, 2025Stifel Nicolaus

Crescent Biopharma price target raised to $32 from $28 at Stifel

Target:$32.00

+146.3%from $12.99

Aug 25, 2025Jefferies

Crescent Biopharma initiated with a Buy at Jefferies

Target:$26.00

+76.9%from $14.70

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance